Considering that GD3S and its ganglioside products, mostly GD3 and GD2, have been clearly implicated in cancer cell properties, including migration, invasion, metastasis, stemness, and EMT transition, targeting GD3S appears as an attractive treatment strategy for GD3/GD2 positive cancers [70]. The gene discussed is ST8SIA1; the disease is cancer.